Skip to main content

Advertisement

Table 2 Baseline characteristics and treatment outcome of two cohorts

From: Pretreatment microRNA levels can predict HBsAg clearance in CHB patients treated with pegylated interferon α-2a

Characteristic Identification Cohort (n = 20) Confirmation Cohort (n = 47)
  HBsAg clearance Non-HBsAg clearance p HBsAg clearance Non-HBsAg clearance p
No. 10 10 17 30
Male sex, No.(%) 9 (90%) 7 (70%) 0.582 15 (88%) 24 (80%) 0.692
aAge, y 29 ± 8.9 46.4 ± 6.8 0.0001*** 39 ± 7.7 38.7 ± 9.3 0.921
History of NAs
 Yes 6 7 1 10 22 0.305
 No 4 3 7 8
Combination of NAs
 Yes 4 4 1 5 8 0.84
 No 6 6   12 22  
cHBV DNA, IU/ml
 undetectable (< 500) 7 9 0.582 16 23 0.228
 500~ 1000 3 1 1 7
bHBsAg at baseline, IU/ml 186.09 (29.31–724.35) 184.28 (62.75–536.69) 1 116.54 (33.36–195.26) 504.36 (156.35–875.49) 0.01
  < 500, No. 7 7 0.549$ 14 15 0.09$
 500~ 1000, No. 2 3 2 10
 1000~ 1500, No. 1 0 1 5
aALT baseline level, IU/ml 36.4 ± 17.83 30.69 ± 9.9 0.388 31.51 ± 14.0 37.21 ± 30.65 0.474
aWBC,× 1012 6.12 ± 1.43 6.08 ± 1.37 0.951 5.98 ± 1.70 5.37 ± 1.28 0.176
Treatment outcome
bPEG-IFN treatment course, w 62.5 (49.8–70.8) 49.5 (39.3–59.5) 0.89 68 (48–72) 71 (48–72.75) 0.789
bHBsAg at EOT, IU/ml 0.01 (0–0.014) 228.3 (11.80–387.92) 1.53E-4*** 0 (0–0.01) 20.86 (2.6–154.47) 1.5783E-8***
Follow-up weeks 56.3 (33.3–93.8) 45.6 (32.4–80) 0.241 25.6 (19.1–37.7) 23.6 (14.3–39.1) 0.542
bHBsAg at follow-up, IU/ml 0.015 (0–0.02) 184.26 (38.45–380.22) 1.44E-4*** 0 (0–0.02) 28.11 (4.94–289.45) 1.637E-8***
  1. $a` = (2*a)/[k*(k-1) + 1] = 0.014, k = 3, a = 0.05; * p < 0.05, **p < 0.01, ***p < 0.001
  2. ALT alanine aminotransferase, WBC white blood count, EOT end of treatment. History of NAs means whether they have used nucles(t)ide analogs (NAs) before PEG-IFN treatment, the NAs include all kinds of conventional medicines: TDF, ETV, LAM, LdT, ADV. They were used by means of monotherapy or combined treatment. The median duration time of NAs was 64.60w (33.3–82.97) (median ± IQR)
  3. adata was presented as mean ± SD
  4. bdata was presented as median (IQR range)
  5. cHBV DNA < 500 IU/ml is undetected in our lab test